Intervention

Cisplatin injection

ClinicalTrials.gov intervention label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov intervention label, found in 8 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials8

Recruiting1

Common conditions10

Lead sponsors shown8

Clinical trials

8 shown

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung CancerNCT06512051 · 2024-07-30

RECRUITING

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung CancerNCT07383116 · 2026-01-15

NOT_YET_RECRUITING

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins MutationsNCT06380348 · 2024-04-26

NOT_YET_RECRUITING

PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLCNCT06375109 · 2024-04-16

NOT_YET_RECRUITING

Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Cisplatin Among Egyptian Non-small Cell Lung Cancer PatientsNCT05746598 · 2020-07-01

UNKNOWN

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)NCT04379635 · 2020-05-29

ACTIVE_NOT_RECRUITING

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLCNCT04363255 · 2020-05-01

UNKNOWN

Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung CancerNCT01631357 · 2014-12-01

COMPLETED

Common conditions

Non Small Cell Lung Cancer2 Advanced or Metastatic Non-small Cell Lung Cancer1 Cardiotoxicity1 Limited-stage Small-cell Lung Cancer1 Local Advanced or Metastatic NSCLC1 Nephropathy1 Non Squamous Non-small Cell Lung Cancer1 Non-small Cell Lung Cancer1 Small Cell Lung Carcinoma1 Squamous Cell Carcinoma1

Leading sponsors

Ain Shams University 1 BeiGene 1 Beijing Chest Hospital, Capital Medical University 1 Shanghai Hengrui Pharmaceutical Co., Ltd. 1 Shanghai Huaota Biopharmaceutical Co., Ltd. 1 Shanghai JMT-Bio Inc. 1 Taizhou Hospital 1 Tianjin Medical University Cancer Institute and Hospital 1

Trial status mix

NOT_YET_RECRUITING3

UNKNOWN2

ACTIVE_NOT_RECRUITING1

COMPLETED1

RECRUITING1

Phase mix

PHASE24

PHASE34

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.